• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ACXP

    Acurx Pharmaceuticals Inc.

    Subscribe to $ACXP
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: acurxpharma.com

    Recent Analyst Ratings for Acurx Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    11/29/2021$12.00Buy
    Maxim Group
    See more ratings

    Acurx Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

      STATEN ISLAND, N.Y., May 13, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2025.   Highlights of the first quarter ended March 31, 2025, or in some cases shortly thereafter, include: In January 2025, the Company announced it had closed a $2.5 million registered direct offering priced at the market under Nasdaq rules.Also in January 2025, we announced that we received positive regulatory guidance from the European Medicines Agency (E

      5/13/25 7:01:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, May 13, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-790-1503; Conference

      4/30/25 7:30:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

      STATEN ISLAND, N.Y., April 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals (NASDAQ:ACXP) (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections today announced that David P. Luci, President & Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase on Wednesday, May 21, 2025, at 9:00 a.m. ET. The Company's lead antibiotic candidate, ibezapolstat (IBZ), is ready to advance to international Phase 3 clinical trials for treatment of patients with C. difficile infection (CDI). A live webcast of the presentation can be found here. A replay o

      4/28/25 7:30:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

      STATEN ISLAND, N.Y., April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Indian Patent Office in March 2025. This patent relates to DNA Polymerase IIIC Inhibitors, including compositions-of-matter. This is the latest in the series of granted patents and pending patent applications that Acurx has filed to protect its proprietary technologies in the field of antimicrobials. To date, Acurx has obtained three U.S. patents, one Israeli patent, one Japanese

      4/17/25 7:30:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

      STATEN ISLAND, N.Y., March 18, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2024.   Highlights of the fourth quarter ended December 31, 2024, or in some cases shortly thereafter, include: In October 2024, we exhibited at ID Week in Los Angeles, which was the annual scientific conference of the Infectious Diseases Society of America and where Drs. Garey and Eubank, from the University of Houston School of Pharm

      3/18/25 7:01:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

      STATEN ISLAND, N.Y., March 10, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the closing of its previously announced registered direct offering of 2,745,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.40 per share (or per common stock equivalent in lieu thereof). In addition, in a concurrent private placement, the Company issued unregistered short-term warrants to purchase up to 8,235,000 shares of common stock. The warrants have an exercise price of

      3/10/25 4:30:00 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

      STATEN ISLAND, N.Y., March 7, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,745,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.40 per share (or per common stock equivalent in lieu thereof) in a registered direct offering. In addition, in a concurrent private placement, the Company will issue unregistered short-term warrants to purchase up to 8,235,000 shar

      3/7/25 8:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

      First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse modelChanges in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VAN)-or metronidazole (MET)-treated groups, complementing prior Phase 2 clinical findings showing IBZ's more selective antibacterial activityNotable differences were observed between the microbiome of IBZ- and fidaxomicin (FDX)-treated groups, which may allow for differentiation of these two anti-CDI antibiotics in future studiesResults establish IBZ differentiating effects on the gut microbiome, indicating a

      3/3/25 8:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., Feb. 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its fourth quarter and full year 2024 financial results on Tuesday, March 18, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, March 18, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-79

      2/28/25 8:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

      Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction between IBZ and its target DNA pol IIIC is conserved across most of the Bacillota phylum, including C. difficile, while certain beneficial taxa are naturally resistant to IBZ, allowing regrowth of resistant microbes known to confer health benefitsThis study used in silico methods to better interpret the narrower than expected ibezapolstat (IBZ) spectrum of activity observed in human trials, which included increased proportion of certain key gut microbiota of the Bacillota phylumIBZ susceptibility of human commensal (nonpathogenic) microbiota was predicted using g

      2/24/25 8:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Acurx Pharmaceuticals Inc. SEC Filings

    See more
    • SEC Form S-1 filed by Acurx Pharmaceuticals Inc.

      S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/21/25 4:16:04 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Acurx Pharmaceuticals Inc.

      D - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/20/25 3:32:14 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Acurx Pharmaceuticals Inc.

      PRE 14A - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/19/25 4:05:41 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/13/25 7:12:47 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Acurx Pharmaceuticals Inc.

      10-Q - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/12/25 4:05:28 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/8/25 4:30:22 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Acurx Pharmaceuticals Inc.

      EFFECT - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      4/15/25 12:15:22 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1 filed by Acurx Pharmaceuticals Inc.

      S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      4/4/25 4:02:47 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      3/28/25 4:10:31 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Acurx Pharmaceuticals Inc.

      D - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      3/20/25 9:13:41 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Acurx Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Acurx Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      11/29/21 8:33:36 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Acurx Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Scodari Joseph C bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 800% to 27,708 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:32:30 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sailer Carl bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 22% to 137,183 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:31:59 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Luci David P bought $50,000 worth of shares (49,261 units at $1.01), increasing direct ownership by 5% to 1,097,458 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:31:33 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Donohue James J. bought $10,000 worth of shares (9,852 units at $1.01), increasing direct ownership by 79% to 22,352 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:31:05 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Deluccia Robert J bought $50,000 worth of shares (49,261 units at $1.01), increasing direct ownership by 5% to 1,010,196 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:30:38 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Dean Jack H bought $10,000 worth of shares (9,852 units at $1.01), increasing direct ownership by 83% to 21,776 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:30:11 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Acurx Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Acurx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

      2/14/24 2:39:21 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

      SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

      2/14/23 11:59:03 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

      SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

      2/14/23 11:52:45 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Acurx Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Shawah Robert G.

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      2/6/25 5:47:58 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Luci David P

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      2/6/25 5:46:58 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Deluccia Robert J

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      2/6/25 5:45:47 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Scodari Joseph C bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 800% to 27,708 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:32:30 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sailer Carl bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 22% to 137,183 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:31:59 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Luci David P bought $50,000 worth of shares (49,261 units at $1.01), increasing direct ownership by 5% to 1,097,458 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:31:33 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Donohue James J. bought $10,000 worth of shares (9,852 units at $1.01), increasing direct ownership by 79% to 22,352 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:31:05 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Deluccia Robert J bought $50,000 worth of shares (49,261 units at $1.01), increasing direct ownership by 5% to 1,010,196 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:30:38 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Dean Jack H bought $10,000 worth of shares (9,852 units at $1.01), increasing direct ownership by 83% to 21,776 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:30:11 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Scodari Joseph C

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      6/18/24 4:15:21 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Acurx Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, May 13, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-790-1503; Conference

      4/30/25 7:30:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., Feb. 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its fourth quarter and full year 2024 financial results on Tuesday, March 18, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, March 18, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-79

      2/28/25 8:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

      STATEN ISLAND, N.Y., Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2024. Highlights of the third quarter ended September 30, 2024, or in some cases shortly thereafter, include: In July 2024, results from the ibezapolstat (IBZ) Phase 2 clinical trial in patients with C. difficile Infection (CDI) were presented at the 17th Biennial Congress of the Anaerobe Society of the Americas by Taryn A. Eubank, PharmD, BCIDP,

      11/13/24 7:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

      STATEN ISLAND, N.Y., Oct. 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2024 financial results on Wednesday, November 13, 2024 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date:                            Wednesday, November 13, 2024 Time:                     

      10/16/24 8:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

      STATEN ISLAND, N.Y., Aug. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2024.  Highlights of the second quarter ended June 30, 2024, or in some cases shortly thereafter, include: In April 2024, we completed a successful End-of-Phase 2 Clinical Meeting with FDA and confirmed Phase 3 Readiness for ibezapolstat (IBZ) to enter Phase 3 clinical trials for the treatment of C. difficile infection. Agreement with FDA was reached

      8/9/24 7:01:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its second quarter 2024 financial results on Friday, August 9, 2024 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date:              Friday, August 9, 2024 Time:                8:00 a.m. ET Toll free (U.S

      7/16/24 7:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update

      STATEN ISLAND, N.Y., May 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2024. Highlights of the first quarter ended March 31, 2024, or in some cases shortly thereafter, include: On January 17, 2024, we announced positive comparative microbiology and microbiome data for ibezapolstat in CDI patients from the Phase 2b clinical trial segment. Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile a

      5/15/24 7:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., April 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:      Date:                           Wednesday, May 15, 2024      Time:                 

      4/23/24 10:57:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

      STATEN ISLAND, N.Y., March 18, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2023.  Highlights of the fourth quarter ended December 31, 2023, or in some cases shortly thereafter, include: In October 2023, we ended enrollment in our Phase 2b clinical trial of ibezapolstat, our lead antibiotic candidate, for the treatment of patients with C. difficile infection, or CDI.In November 2023, we reported top-li

      3/18/24 7:01:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., March 4, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its fourth quarter and full year 2023 financial results on Monday, March 18, 2024, at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Monday, March 18, 2024 Time: 8:00 a.m. ET Toll free (U.S.): 877-790-1

      3/4/24 7:01:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care